| 229.35 BATS BZX Real-Time Price As of 12:37pm ET |  +2.96 / +1.31%Today’s Change | 216.12 Today|||52-Week Range 388.67 | -23.78% Year-to-Date |
| Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? 10:58am / Zacks.com - Paid Partner Content | 2 Beaten Down Bluechips: Are They Buys? Apr 17 / MotleyFool.com - Paid Partner Content |
| Will Bristol-Myers (BMY) Disappoint This Earnings Season? 9:05am / Zacks.com - Paid Partner Content | Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Apr 17 / Zacks.com - Paid Partner Content |
| Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs Apr 18 / Zacks.com - Paid Partner Content | Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Apr 15 / Zacks.com - Paid Partner Content |
| 2 Beaten-Down Blue Chips: Are They Buys? Apr 17 / MotleyFool.com - Paid Partner Content | Better Buy: Gilead Sciences vs. Biogen Apr 14 / MotleyFool.com - Paid Partner Content |
| Here's Why Ionis Pharmaceuticals Slumped Today Apr 17 / MotleyFool.com - Paid Partner Content | Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Apr 09 / Zacks.com - Paid Partner Content |
| Previous close | 226.39 |
| Today’s open | 226.57 |
| Day’s range | 226.57 - 232.17 |
| Volume | 968,274 |
| Average volume (3 months) | 1,993,482 |
| Market cap | $44.5B |
| Earnings growth (last year) | +81.10% |
| Earnings growth (this year) | +10.04% |
| Earnings growth (next 5 years) | +2.30% |
| Revenue growth (last year) | +9.67% |
| P/E ratio | 10.6 |
| Price/Sales | 5.13 |
| Price/Book | 3.42 |
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | -1.84 | -0.58% |
| EXASExact Sciences Corp | +0.04 | +0.04% |
| GILDGilead Sciences | -0.59 | -0.94% |
| BLUEbluebird bio Inc | -2.34 | -1.71% |
| Next reporting date | April 24, 2019 |
| EPS forecast (this quarter) | $6.83 |
| Annual revenue (last year) | $12.1B |
| Annual profit (last year) | $4.4B |
| Net profit margin | 36.76% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Michel Vounatsos |
Chief Financial Officer & Executive Vice President Jeffrey D. Capello |
Corporate headquarters Cambridge, Massachusetts |
